444 related articles for article (PubMed ID: 27958275)
1. ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.
Williamson CT; Miller R; Pemberton HN; Jones SE; Campbell J; Konde A; Badham N; Rafiq R; Brough R; Gulati A; Ryan CJ; Francis J; Vermulen PB; Reynolds AR; Reaper PM; Pollard JR; Ashworth A; Lord CJ
Nat Commun; 2016 Dec; 7():13837. PubMed ID: 27958275
[TBL] [Abstract][Full Text] [Related]
2. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
Zheng H; Shao F; Martin S; Xu X; Deng CX
Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.
Miller RE; Brough R; Bajrami I; Williamson CT; McDade S; Campbell J; Kigozi A; Rafiq R; Pemberton H; Natrajan R; Joel J; Astley H; Mahoney C; Moore JD; Torrance C; Gordan JD; Webber JT; Levin RS; Shokat KM; Bandyopadhyay S; Lord CJ; Ashworth A
Mol Cancer Ther; 2016 Jul; 15(7):1472-84. PubMed ID: 27364904
[TBL] [Abstract][Full Text] [Related]
4. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells.
Schoonen PM; Kok YP; Wierenga E; Bakker B; Foijer F; Spierings DCJ; van Vugt MATM
Mol Oncol; 2019 Nov; 13(11):2422-2440. PubMed ID: 31529615
[TBL] [Abstract][Full Text] [Related]
5. Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy.
Xu S; Sak A; Niedermaier B; Erol YB; Groneberg M; Mladenov E; Kang M; Iliakis G; Stuschke M
Front Oncol; 2022; 12():999626. PubMed ID: 36249060
[TBL] [Abstract][Full Text] [Related]
6. ZEB1 inhibition sensitizes cells to the ATR inhibitor VE-821 by abrogating epithelial-mesenchymal transition and enhancing DNA damage.
Song N; Jing W; Li C; Bai M; Cheng Y; Li H; Hou K; Li Y; Wang K; Li Z; Liu Y; Qu X; Che X
Cell Cycle; 2018; 17(5):595-604. PubMed ID: 29157079
[TBL] [Abstract][Full Text] [Related]
7. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents.
Cui Y; Palii SS; Innes CL; Paules RS
Cell Cycle; 2014; 13(22):3541-50. PubMed ID: 25483091
[TBL] [Abstract][Full Text] [Related]
8. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
[TBL] [Abstract][Full Text] [Related]
9. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
[TBL] [Abstract][Full Text] [Related]
10. ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
Shen J; Peng Y; Wei L; Zhang W; Yang L; Lan L; Kapoor P; Ju Z; Mo Q; Shih IeM; Uray IP; Wu X; Brown PH; Shen X; Mills GB; Peng G
Cancer Discov; 2015 Jul; 5(7):752-67. PubMed ID: 26069190
[TBL] [Abstract][Full Text] [Related]
11. Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.
Middleton FK; Patterson MJ; Elstob CJ; Fordham S; Herriott A; Wade MA; McCormick A; Edmondson R; May FE; Allan JM; Pollard JR; Curtin NJ
Oncotarget; 2015 Oct; 6(32):32396-409. PubMed ID: 26486089
[TBL] [Abstract][Full Text] [Related]
12. A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers.
Hocke S; Guo Y; Job A; Orth M; Ziesch A; Lauber K; De Toni EN; Gress TM; Herbst A; Göke B; Gallmeier E
Oncotarget; 2016 Feb; 7(6):7080-95. PubMed ID: 26755646
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
Jackson CB; Noorbakhsh SI; Sundaram RK; Kalathil AN; Ganesa S; Jia L; Breslin H; Burgenske DM; Gilad O; Sarkaria JN; Bindra RS
Cancer Res; 2019 Sep; 79(17):4331-4338. PubMed ID: 31273061
[TBL] [Abstract][Full Text] [Related]
14. Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer.
Yamada L; Saito M; Thar Min AK; Saito K; Ashizawa M; Kase K; Nakajima S; Onozawa H; Okayama H; Endo H; Fujita S; Sakamoto W; Saze Z; Momma T; Mimura K; Ohki S; Kono K
Gastric Cancer; 2021 Jan; 24(1):60-71. PubMed ID: 32506298
[TBL] [Abstract][Full Text] [Related]
15. Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.
Nikkilä J; Kumar R; Campbell J; Brandsma I; Pemberton HN; Wallberg F; Nagy K; Scheer I; Vertessy BG; Serebrenik AA; Monni V; Harris RS; Pettitt SJ; Ashworth A; Lord CJ
Br J Cancer; 2017 Jun; 117(1):113-123. PubMed ID: 28535155
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.
Wang C; Wang G; Feng X; Shepherd P; Zhang J; Tang M; Chen Z; Srivastava M; McLaughlin ME; Navone NM; Hart GT; Chen J
Oncogene; 2019 Apr; 38(14):2451-2463. PubMed ID: 30532030
[TBL] [Abstract][Full Text] [Related]
17. Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors.
Job A; Schmitt LM; von Wenserski L; Lankat-Buttgereit B; Gress TM; Buchholz M; Gallmeier E
Neoplasia; 2018 Nov; 20(11):1135-1143. PubMed ID: 30257222
[TBL] [Abstract][Full Text] [Related]
18. A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.
Qiu Z; Fa P; Liu T; Prasad CB; Ma S; Hong Z; Chan ER; Wang H; Li Z; He K; Wang QE; Williams TM; Yan C; Sizemore ST; Narla G; Zhang J
Cancer Res; 2020 Aug; 80(16):3305-3318. PubMed ID: 32522823
[TBL] [Abstract][Full Text] [Related]
19. Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
Ngoi NY; Sundararajan V; Tan DS
Int J Gynecol Cancer; 2020 Aug; 30(8):1224-1238. PubMed ID: 32571890
[TBL] [Abstract][Full Text] [Related]
20. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]